.jpg "Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE)")
In a report issued on August 2, Gena Wang from Barclays maintained a Buy rating on Ultragenyx Pharmaceutical, Inc. (RARE), with a price target of $87. The company’s shares closed on Friday at $55.66.
According to TipRanks.com, Wang is a 5-star analyst with an average return of 19.8% and a 49.4% success rate. Wang covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Meiragtx Holdings Plc, and Mirati Therapeutics.
Currently, the analyst consensus on Ultragenyx Pharmaceutical, Inc. is a Strong Buy with an average price target of $79, which is a 41.9% upside from current levels. In a report issued on August 2, Cowen & Co. also reiterated a Buy rating on the stock with a $79 price target.
See today’s analyst top recommended stocks >>
Based on Ultragenyx Pharmaceutical, Inc.’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $99.17 million. In comparison, last year the company had a GAAP net loss of $52.73 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.
